- Proven leader with deep experience building oncology businesses -
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN) a biotechnology company developing targeted
cancer therapeutics using its proprietary antibody-drug conjugate (ADC)
technology, today announced that Mark J. Enyedy has been appointed
President and CEO and elected to the Board of Directors, effective May
16, 2016. Mr. Enyedy succeeds Daniel Junius, who as previously announced
is retiring from these positions and will continue to serve on
ImmunoGen's Board.
"Today, ImmunoGen has a rich pipeline of wholly-owned oncology product
candidates, validated technology, and strong research," said Stephen
McCluski, Chairman of the Board. "Mark's proven leadership skills,
combined with his deep experience building science-based oncology
businesses, make him ideally suited to take ImmunoGen to the next level."
Mr. Enyedy, 52, brings over 25 years of combined general management,
business development and legal experience in the biotechnology industry.
He joins ImmunoGen from Shire plc, where he served as Executive Vice
President and Head of Corporate Development, leading the company's
Strategy, M&A, and Corporate Planning functions and providing commercial
oversight for the company's pre-Phase 3 portfolio. Previously, Mr.
Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15
years at Genzyme Corporation in diverse roles, most recently as
President of the Transplant, Oncology, and Multiple Sclerosis divisions.
During his tenure at Genzyme, Mr. Enyedy developed and executed the
company's strategy to enter the oncology market, overseeing the launch
of two new products and managing a global business generating over $675
million in revenue with operations in more than 50 countries.
Before joining Genzyme, Mr. Enyedy was an associate with the Boston law
firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S.
from Northeastern University. Mr. Enyedy also serves on the Board of
Directors of Fate Therapeutics.
"I am pleased to be joining ImmunoGen at such an important time in the
Company's evolution and helping to build upon its leadership position in
the exciting ADC field," said Mr. Enyedy. "With a lead product in
later-stage testing for ovarian cancer, a strong portfolio of
earlier-stage candidates, and a productive technology platform,
ImmunoGen is well-positioned for sustainable innovation in oncology and
value creation for shareholders. I look forward to working with the
company's outstanding leadership team, dedicated employees, and global
partners to develop and commercialize novel ADC therapies, which hold
the potential to deliver better outcomes for cancer patients across an
expanding range of indications."
"It has been a privilege to serve as the CEO of ImmunoGen over these
past seven years, and I am delighted to have Mark as my successor," said
Mr. Junius. "Mark's experience, vision, and leadership skills will
enable ImmunoGen to realize its full potential in developing better
therapies for cancer patients."
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted anticancer therapeutics using its proprietary ADC technology.
The Company has four wholly owned clinical-stage ADCs. The lead,
mirvetuximab soravtansine, is in Phase 2 testing for the treatment of
folate receptor α-positive ovarian cancer. ImmunoGen's ADC technology is
used in Roche's marketed product, Kadcyla®, and in agents in
development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis,
Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.
ImmunoGen Forward-Looking Statement
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer agents. A
review of these risks can be found in ImmunoGen's Annual Report on Form
10-K for the fiscal year ended June 30, 2015 and other reports filed
with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160426005304/en/
ImmunoGen, Inc.
For Investors:
Carol Hausner, 781-895-0600
info@immunogen.com
or
For
Media:
Michael Lampe,
484-575-5040
michael@scientpr.com
Source: ImmunoGen, Inc.
News Provided by Acquire Media